Intravitreal Ranibizumab and/or Dexamethasone Implant for Macular Edema Secondary to Retinal Vein Occlusion

被引：10

作者：

Nghiem-Buffet, Sylvia ^{[1
,3
]}

Fajnkuchen, Franck ^{[1
,3
]}

Buffet, Marc ^{[2
]}

Ayrault, Sandrine ^{[1
]}

Le Gloahec-Lorcy, Anna ^{[1
]}

Grenet, Typhaine. ^{[1
,3
]}

Delahaye-Mazza, Corinne ^{[1
]}

Quentel, Gabriel ^{[1
]}

Cohen, Salomon Y. ^{[1
]}

机构：

[1] Ctr Ophtalmol Imagerie & Laser, FR-75015 Paris, France

[2] Inst Arthur Vernes, Paris, France

[3] Univ Paris 13, Hop Avicenne, APHP, Dept Ophthalmol, Bobigny, France

来源：

OPHTHALMOLOGICA | 2014年 / 232卷 / 04期

关键词：

Retinal vein occlusion; Central retinal vein occlusion; Branch retinal vein occlusion; Ranibizumab; Dexamethasone implant; Macular edema; Anti-VEGF therapy; ENDOTHELIAL GROWTH-FACTOR; SUSTAINED BENEFITS; 12-MONTH OUTCOMES; VISUAL-ACUITY; STANDARD-CARE; BRANCH; BEVACIZUMAB; TRIAMCINOLONE; EFFICACY; OZURDEX;

D O I：

10.1159/000365639

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose: To investigate the outcome of intravitreal ranibizumab and/or dexamethasone implant treatment for treatment of macular edema (ME) secondary to central or branch retinal vein occlusion (CRVO or BRVO) in a clinical setting. Methods: Retrospective analysis of consecutive patients followed for at least 6 months. Data recorded included the type of occlusion, initial and final visual acuity, and number of injections. Results: Sixty-five patients were included, 26 had CRVO and 39 BRVO. Mean (+/-SD) follow-up duration was 16 (+/-7.7) months. Twenty-four (36.9%) patients received ranibizumab in monotherapy, 19 patients (29.3%) dexamethasone in monotherapy, and 22 patients (33.8%) received successively both treatments. In dexamethasone-treated patients, mean (+/-SD) visual acuity gain was 5.8 +/- 10.7 letters for BRVO and 16.8 +/- 15.6 letters for CRVO. In ranibizumab-treated patients, mean (+/-SD) visual acuity gain was 9.2+/-10 letters for BRVO and 18.2+/-20.5 letters for CRVO. Conclusion: Both intravitreal ranibizunnab and dexamethasone intravitreal implant could be used as first-line therapy for patients with ME secondary to retinal vein occlusion. (C) 2014 S. Karger AG, Basel

引用

页码：216 / 222

页数：7

共 46 条

[1] VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].

AIELLO, LP ;

AVERY, RL ;

ARRIGG, PG ;

KEYT, BA ;

JAMPEL, HD ;

SHAH, ST ;

PASQUALE, LR ;

THIEME, H ;

IWAMOTO, MA ;

PARK, JE ;

NGUYEN, HV ;

AIELLO, LM ;

FERRARA, N ;

KING, GL .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487

[2]

[Anonymous], 1984, AM J OPHTHALMOL, V98, P271

[3] Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content - Vascular endothelial growth factor decreases occludin in retinal endothelial cells [J].

Antonetti, DA ;

Barber, AJ ;

Khin, S ;

Lieth, E ;

Tarbell, JM ;

Gardner, TW .

DIABETES, 1998, 47 (12) :1953-1959

[4] Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up - The SOLO study [J].

Bezatis, Athanasios ;

Spital, Georg ;

Hoehn, Fabian ;

Maier, Mathias ;

Clemens, Christoph R. ;

Wachtlin, Joachim ;

Lehmann, Florian ;

Hattenbach, Lars Olof ;

Feltgen, Nicolas ;

Meyer, Carsten H. .

ACTA OPHTHALMOLOGICA, 2013, 91 (05) :E340-E347

[5]

Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022

[6] Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study [J].

Brown, David M. ;

Campochiaro, Peter A. ;

Bhisitkul, Robert B. ;

Ho, Allen C. ;

Gray, Sarah ;

Saroj, Namrata ;

Adamis, Anthony P. ;

Rubio, Roman G. ;

Murahashi, Wendy Yee .

OPHTHALMOLOGY, 2011, 118 (08) :1594-1602

[7] Ranibizumab for macular edema due to retinal vein occlusions: Implication of VEGF as a critical stimulator [J].

Campochiaro, Peter A. ;

Hafiz, Gulnar ;

Shah, Syed Mahmood ;

Nguyen, Quan Dong ;

Ying, Howard ;

Do, Diana V. ;

Quinlan, Edward ;

Zimmer-Galler, Ingrid ;

Haller, Julia A. ;

Solomon, Sharon D. ;

Sung, Jennifer U. ;

Hadi, Yasmin ;

Janjua, Kashif A. ;

Jawed, Nida ;

Choy, David F. ;

Arron, Joseph R. .

MOLECULAR THERAPY, 2008, 16 (04) :791-799

[8] Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study [J].

Campochiaro, Peter A. ;

Brown, David M. ;

Awh, Carl C. ;

Lee, S. Young ;

Gray, Sarah ;

Saroj, Namrata ;

Murahashi, Wendy Yee ;

Rubio, Roman G. .

OPHTHALMOLOGY, 2011, 118 (10) :2041-2049

[9] Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study [J].

Campochiaro, Peter A. ;

Heier, Jeffrey S. ;

Feiner, Leonard ;

Gray, Sarah ;

Saroj, Namrata ;

Rundle, Amy Chen ;

Murahashi, Wendy Yee ;

Rubio, Roman G. .

OPHTHALMOLOGY, 2010, 117 (06) :1102-U111

[10] LONGER-TERM OUTCOMES OF A PROSPECTIVE STUDY OF INTRAVITREAL RANIBIZUMAB AS A TREATMENT FOR DECREASED VISUAL ACUITY SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION [J].

Chang, Louis K. ;

Spaide, Richard F. ;

Klancnik, James M. ;

Sorenson, John ;

Slakter, Jason S. ;

Freund, K. Bailey ;

Yannuzzi, Lawrence A. ;

Tseng, Joseph J. ;

Klein, Robert .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2011, 31 (05) :821-828

← 1 2 3 4 5 →